What is Outpace Bio?
Based in Seattle, WA, Outpace Bio is a biotechnology company focused on addressing persistent challenges in anticancer T cell therapies and other cell and gene therapy applications. Leveraging protein design and synthetic biology, the company is developing smart cell therapies to advance the field. Outpace Bio's approach aims to overcome existing limitations in therapeutic efficacy and patient outcomes within the rapidly evolving landscape of cell and gene therapy.
How much funding has Outpace Bio raised?
Outpace Bio has raised a total of $174M across 2 funding rounds:
Series A
$30M
Series B
$144M
Series A (2021): $30M with participation from Lyell Immunopharma, WRF Capital, Sahsen Ventures, ARTIS Ventures, Abstract Ventures, Mubadala, Civilization Ventures, and Playground
Series B (2024): $144M led by Qatar Investment Authority, WRF Capital, and RA Capital Management
Key Investors in Outpace Bio
Qatar Investment Authority
Qatar Investment Authority is the sovereign wealth fund of the State of Qatar, managing global financial assets across diverse classes to generate sustainable long-term returns and support national economic development.
RA Capital Management
RA Capital Management is a multi-stage investment manager focused on public and private healthcare and life science companies, including those developing drugs, medical devices, and diagnostics, with a growing interest in climate and sustainability technologies.
Lyell Immunopharma
Lyell Immunopharma is a clinical-stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, pioneering novel technologies to address major barriers in solid tumor cell therapy.
What's next for Outpace Bio?
With the recent major strategic investment, Outpace Bio is poised for significant expansion and further research and development. The company's focus on novel cell therapies, particularly for challenging conditions like solid tumors, suggests a strategic direction towards clinical validation and potential commercialization. This funding will likely fuel advancements in their proprietary protein design platforms and synthetic biology tools, enabling them to tackle complex biological problems and solidify their position in the therapeutic innovation market. Continued investment from prominent venture capital firms indicates strong confidence in Outpace Bio's scientific approach and market potential.
See full Outpace Bio company page
